Login to Your Account


Peering through the MYSTIC

Astrazeneca plc's failure with the phase III MYSTIC trial in non-small-cell lung cancer had investors asking what's next, and the $8.5 billion deal with Merck & Co. Inc. around Lynparza wasn't enough to satisfy them.

more »


Analysis

Merck & Co. Inc. took cardiovascular disease (CVD) experts – and, perhaps, some of its own decision-makers – by surprise last month when it disclosed that the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of its cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, met its primary endpoint by reducing major coronary events (defined as the composite of coronary death, myocardial infarction and coronary revascularization) compared to placebo in patients at risk for cardiac events who were already receiving a regimen to lower low-density lipoprotein, or LDL.

read more »

Our Habitat for All Things Science
HIV's dual penicillin moment: possible cure, definite resistance
Opinion


Partners in Focus